Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 13/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178065 | 0.85 | STING1 (0.54) | STING1GPR84 | |
| SCHEMBL28736881 | 0.82 | STING1 (0.74) | STING1GPR84NR4A2CREBBPPBRM1 | |
| SCHEMBL384965 | 0.81 | STING1 (0.63) | STING1GPR84 | |
| SCHEMBL4490274 | 0.81 | STING1 (0.59) | STING1GPR84NR4A2CREBBP | |
| SCHEMBL1596152 | 0.79 | STING1 (0.61) | STING1GPR84NR4A2CREBBPPBRM1 | |
| SCHEMBL4103760 | 0.79 | STING1 (0.60) | STING1NR4A2CREBBPPBRM1 | |
| SCHEMBL5894412 | 0.78 | STING1 (0.56) | STING1GPR84 | |
| SCHEMBL4092376 | 0.78 | STING1 (0.59) | STING1 | |
| SCHEMBL13134373 | 0.77 | STING1 (0.56) | STING1GPR84 | |
| SCHEMBL23167581 | 0.77 | STING1 (0.58) | STING1GPR84NR4A2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431029-B1 | Method of inhibiting prostate cancer cell proliferation | SCOTT KIERAN FRANCIS (AU) | 2014-07-30 | — | — | EP | disclosed |
| EP-1531803-B1 | METHOD OF INHIBITING PROSTATE CANCER CELL PROLIFERATION | SCOTT KIERAN FRANCIS (AU) | 2013-05-15 | — | — | EP | disclosed |
| EP-2431029-A2 | Method of inhibiting prostate cancer cell proliferation | Scott, Kieran Francis (AU) | 2012-03-21 | — | — | EP | disclosed |
| US-8026271-B2 | Formulations of indol-3-yl-2-oxoacetamide compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-09-27 | — | — | US | disclosed |
| US-20110195915-A1 | Method of inhibiting prostate cancer cell proliferation | SCOTT, KIERAN, FRANCIS (AU) | 2011-08-11 | — | — | US | disclosed |
| US-7919458-B2 | Using phospholipase inhibitor as therapeutic in treatment of cancer disorders | SCOTT, KIERAN, FRANCIS (AU) | 2011-04-05 | — | — | US | disclosed |
| US-7662834-B2 | Methods of 1H-indol-3-yl-2-oxoacetamide compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-02-16 | — | — | US | disclosed |
| EP-1531803-A4 | METHOD OF INHIBITING PROSTATE CANCER CELL PROLIFERATION | SCOTT KIERAN FRANCIS (AU) | 2009-08-05 | — | — | EP | disclosed |
| EP-1569902-B1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7396838-B2 | Use of 1H-indol-3-yl-2-oxoacetamide compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-07-08 | — | — | US | disclosed |
| EP-1569902-A1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6903104-B2 | Indol-3-YL-2-oxoacetamide compounds and methods of use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2005-06-07 | — | — | US | disclosed |
| EP-1531803-A1 | METHOD OF INHIBITING PROSTATE CANCER CELL PROLIFERATION | Scott, Kieran Francis (AU) | 2005-05-25 | — | — | EP | disclosed |
| US-20040266762-A1 | Indole derivatives having an apoptosis-inducing effect | AETERNA ZENTARIS GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
| WO-2004064822-A1 | METHOD OF INHIBITING PROSTATE CANCER CELL PROLIFERATION | SCOTT KIERAN FRANCIS (AU) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004052856-A1 | SUBSTITUTED INDOLE OXO-ACETYL AMINO ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| CN-1413205-A | 2- (1H-indol-3-yl) -2-oxo-acetamides with antitumor activity | NOVUSPHARMA SPA (IT) | 2003-04-23 | — | — | CN | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266762-A1 | Indole derivatives having an apoptosis-inducing effect | BAD, API5, AIFM1 | STING1 1342/4885GPR84 1113/4885CYP2A6 2480/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | STING1 2460/4885GPR84 1923/4885CYP2A6 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.